The latest price target for Purple Biotech (NASDAQ:PPBT) was reported by HC Wainwright & Co. on November 15, 2024. The analyst firm set a price target for $33.00 expecting PPBT to rise to within 12 months (a possible 1122.22% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Purple Biotech (NASDAQ:PPBT) was provided by HC Wainwright & Co., and Purple Biotech reiterated their buy rating.

There is no last upgrade for Purple Biotech

There is no last downgrade for Purple Biotech.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Purple Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Purple Biotech was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Purple Biotech (PPBT) rating was a reiterated with a price target of $33.00 to $33.00. The current price Purple Biotech (PPBT) is trading at is $2.70, which is out of the analyst’s predicted range.